A Multicenter Study of Grepafloxacin and Clarithromycin in the Treatment of Patients With Community-Acquired Pneumonia

Efficacy and Tolerability of Once-Daily Telithromycin Compared with High-Dose Amoxicillin for Treatment of Community-Acquired Pneumonia

“…For example, causative pathogens were isolated in 26% (131/504) of patients with CAP who took part in a similar study comparing the efficacies of grepafloxacin and clarithromycin [40]. As expected, S. pneumoniae and H. influenzae were the pathogens most commonly isolated in the present study.…”

Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia

“…New fluoroquinolones in monotherapy, such as moxifloxacin, gatifloxacin or levofloxacin, have been suggested as first-line antibiotics in CAP. Several studies have compared new fluoroquinolones with amoxicillin [28][29][30][31] or with second-and thirdgeneration cephalosporin [32][33][34][35] or macrolide, such as clarithromycin [36][37][38][39][40][41]. However, no single study has embraced all of the therapeutically recognised options in CAP in an effectiveness analysis like that conducted in the present investigation.…”

Respiratory tract infections by Mycoplasma pneumoniae in children: a review of diagnostic and therapeutic measures

“…Both compounds had a in vitro minimal inhibitory concentration of 90% of the strains tested of 0.125 mg/l. In clinical trials in adults with communityacquired pneumonia treated with grepa¯oxacin, itshowed clinical success rates of 76% to 90% and eradication of 89% to 95% of the pathogens involved [101,104,125]. These studies also showed that it was well tolerated; however, grepa¯oxacin has been recently withdrawn because it caused ventricular tachycardia linked to excessive QT interval prolongation [5,106].…”